Fig. 1: Flow diagram of participant enrollment, treatment, and analysis. | Nature Communications

Fig. 1: Flow diagram of participant enrollment, treatment, and analysis.

From: Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial

Fig. 1: Flow diagram of participant enrollment, treatment, and analysis.The alternative text for this image may have been generated using AI.

A total of 69 patients were screened for eligibility in the trial. Twenty patients were excluded according to the inclusion and exclusion criteria. Forty-nine eligible patients were enrolled and administered two cycles of induction chemotherapy plus camrelizumab. Three patients discontinued the study treatment due to failure to receive subsequent chemoradiotherapy as per the study protocol. All 49 enrolled patients were included in the intention-to-treat analysis, while 46 patients who completed the full treatment protocol were included in the per-protocol analysis.

Back to article page